

9 February 2026

## MEDICARE CONTRACTOR NOVITAS SCHEDULES EXPERT PANEL

**DUNEDIN, New Zealand** – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) notes its Medicare Administrative Contractor (MAC) Novitas has confirmed the scheduling of its planned Contractor Advisory Committee (CAC) to consider the evidence for urine biomarkers in patients with hematuria.

The opinions expressed during the meeting, which is scheduled to take place from 6:00pm on 19 February 2026, US ET (12:00pm Friday 20 February 2026 NZST), are expected to have an influence over the language Novitas uses in any draft Local Coverage Determination (LCD) covering Medicare reimbursement of Cxbladder that is published following the meeting.

The WebEx meeting is estimated to run for two hours and is public to the public by registering at the link below.

<https://fcso.webex.com/weblink/register/red3f833b75a2f3922d04ada5d71a6aee>

Given the significance of the CAC, Pacific Edge expects its shares to enter a trading halt ahead of the meeting that is expected to last until the company provides an announcement to investors giving context to the matters covered at the CAC. The company expects to make this announcement ahead of the market open on Monday 23 February 2026 (NZST).

*Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.*

**Pacific Edge:** [www.pacifiedgedx.com](http://www.pacifiedgedx.com)

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

**Cxbladder:** [www.cxbladder.com](http://www.cxbladder.com)

Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with microhematuria and those being monitored for recurrent disease. The tests help improve the overall patient experience, while prioritizing time and clinical resources to optimize practice workflow and improve efficiency.

Supported by over 20 years of research, Cxbladder's evidence portfolio extends to more than 25 peer reviewed publications, and Cxbladder Triage is now included in the American Urological Association's Microhematuria Guideline. To drive increased adoption and improved patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies designed to generate further clinical utility evidence.

Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South America. In the US, the test has been used by over 5,000 urologists who have ordered more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public healthcare and all residents have the option of buying the test online.